Drawing for STOP

USPTO serial 88902309

STOP

Reviewed by CopyMark Law Group

Status 606
Filing date
Status date
Registration date
—
Examiner
DEAN, JULES J.
Law office
INTENT TO USE SECTION

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with STOP?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Jennifer S. Stachniak

Jennifer S. Stachniak JOHNSON, MARCOU, ISAACS & NIX, LLCP.O. BOX 691HOSCHTON, GA 30548UNITED STATES

Goods and services

ClassDescriptionStatusFirst use
001Diagnostic preparations for scientific or research use; Reagent paper other than for medical purposesACTIVE—
005RNA-guided therapeutic pharmaceuticals for the treatment of diseases and medical conditions, namely, allergies, autoimmune diseases and disorders, autoinflammatory diseases and disorders, bacterial infections, mycoses, blood diseases and disorders, cancer, cardiovascular diseases and disorders, chromosomal diseases and disorders, congenital diseases and abnormalities, hereditary diseases and abnormalities, neonatal diseases and abnormalities, cognitive diseases and disorders, connective tissue diseases and disorders, digestive system diseases and disorders, diabetes, ear, nose, and throat diseases and disorders, endocrine system diseases and disorders, female urogenital diseases and disorders, female reproductive diseases and disorders, pregnancy complications, fungal infections, genetic diseases and disorders, gastro-intestinal diseases and disorders, hemic and lymphatic diseases and disorders, hereditary cancer syndromes, heart diseases and disorders, hormonal diseases and disorders, immune system diseases and disorders, immunodeficiency diseases and disorders, infectious disease, inflammatory diseases and disorders, kidney and urinary diseases and disorders, lung diseases and disorders, male reproductive diseases and disorders, male urogenital diseases and disorders, mouth diseases and disorders, musculoskeletal diseases and disorders, neoplasms, nervous system diseases and disorders, neurological diseases and disorders, neuropsychiatric diseases and disorders, nutritional and metabolic diseases, ocular diseases and disorders, otorhinolaryngologic diseases, parasitic infections, respiratory diseases and disorders, skin and connective tissue diseases, stomatognathic diseases and disorders, chemical imbalances, viral infections; diagnostic preparations for medical or veterinary purposes; Reagent paper for medical or veterinary purposes; Diagnostic kits comprised of medical diagnostic reagents and assays for testing of bodily fluids for use in disease detection, namely, allergies, autoimmune diseases and disorders, autoinflammatory diseases and disorders, bacterial infections, mycoses, blood diseases and disorders, cancer, cardiovascular diseases and disorders, chromosomal diseases and disorders, congenital diseases and abnormalities, hereditary diseases and abnormalities, neonatal diseases and abnormalities, cognitive diseases and disorders, connective tissue diseases and disorders, digestive system diseases and disorders, diabetes, ear, nose, and throat diseases and disorders, endocrine system diseases and disorders, female urogenital diseases and disorders, female reproductive diseases and disorders, pregnancy complications, fungal infections, genetic diseases and disorders, gastro-intestinal diseases and disorders, hemic and lymphatic diseases and disorders, hereditary cancer syndromes, heart diseases and disorders, hormonal diseases and disorders, immune system diseases and disorders, immunodeficiency diseases and disorders, infectious disease, inflammatory diseases and disorders, kidney and urinary diseases and disorders, lung diseases and disorders, male reproductive diseases and disorders, male urogenital diseases and disorders, mouth diseases and disorders, musculoskeletal diseases and disorders, neoplasms, nervous system diseases and disorders, neurological diseases and disorders, neuropsychiatric diseases and disorders, nutritional and metabolic diseases, ocular diseases and disorders, otorhinolaryngologic diseases, parasitic infections, respiratory diseases and disorders, skin and connective tissue diseases, stomatognathic diseases and disorders, chemical imbalances, viral infections; Medical diagnostic reagents and assays for testing of body fluidsACTIVE—
044Disease and pest control treatments for agriculture, namely, breeding and propagating genetically modified plants with increased disease resistance; performing diagnosis of diseases; Medical testing for diagnostic or treatment purposes; Providing medical information from a website; Providing a website featuring information in the field of the diagnosis and treatment of allergies, autoimmune diseases and disorders, autoinflammatory diseases and disorders, bacterial infections, mycoses, blood diseases and disorders, cancer, cardiovascular diseases and disorders, chromosomal diseases and disorders, congenital diseases and abnormalities, hereditary diseases and abnormalities, neonatal diseases and abnormalities, cognitive diseases and disorders, connective tissue diseases and disorders, digestive system diseases and disorders, diabetes, ear, nose, and throat diseases and disorders, endocrine system diseases and disorders, female urogenital diseases and disorders, female reproductive diseases and disorders, pregnancy complications, fungal infections, genetic diseases and disorders, gastro-intestinal diseases and disorders, hemic and lymphatic diseases and disorders, hereditary cancer syndromes, heart diseases and disorders, hormonal diseases and disorders, immune system diseases and disorders, immunodeficiency diseases and disorders, infectious disease, inflammatory diseases and disorders, kidney and urinary diseases and disorders, lung diseases and disorders, male reproductive diseases and disorders, male urogenital diseases and disorders, mouth diseases and disorders, musculoskeletal diseases and disorders, neoplasms, nervous system diseases and disorders, neurological diseases and disorders, neuropsychiatric diseases and disorders, nutritional and metabolic diseases, ocular diseases and disorders, otorhinolaryngologic diseases, parasitic infections, respiratory diseases and disorders, skin and connective tissue diseases, stomatognathic diseases and disorders, chemical imbalances, viral infectionsACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

Latest event (MAB6): The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.

DateCodeEventWhat it means
Dec 11, 2023MAB6ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
Dec 11, 2023ABN6ABANDONMENT - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
Jun 21, 2023DOCKASSIGNED TO EXAMINER—
May 9, 2023NOAMNOA E-MAILED - SOU REQUIRED FROM APPLICANTA Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date.
Mar 14, 2023NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Mar 14, 2023PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Feb 22, 2023NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Feb 9, 2023CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Jan 13, 2023RCCKSUSPENSION CHECKED - TO ATTORNEY FOR ACTION—
Jan 9, 2023DOCKASSIGNED TO EXAMINER—
Dec 13, 2022RCCKSUSPENSION CHECKED - TO ATTORNEY FOR ACTION—
May 6, 2022RCSCREPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED—
Sep 13, 2021RCSCREPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED—
Feb 10, 2021GNS3NOTIFICATION OF LETTER OF SUSPENSION E-MAILED—
Feb 10, 2021GNSLLETTER OF SUSPENSION E-MAILED—
Feb 10, 2021CNSLSUSPENSION LETTER WRITTEN—
Feb 4, 2021TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Feb 4, 2021CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Feb 4, 2021TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Aug 4, 2020GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Aug 4, 2020GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Aug 4, 2020CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jul 29, 2020DOCKASSIGNED TO EXAMINER—
May 19, 2020MDSCNOTICE OF DESIGN SEARCH CODE E-MAILED—
May 17, 2020NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
May 8, 2020NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance